Epigral Posts Record Q4 FY26 Revenue as Expansion Momentum Builds

Epigral Limited achieved its highest-ever revenue of INR 736 crore in the fourth quarter of fiscal year 2026. This represents a significant 22% increase from the previous quarter. The company also reported a strong EBITDA of INR 169 crore, a jump of 64% quarter-on-quarter, with profit margins reaching 23%.

While the fourth quarter showed robust growth, consolidated revenue for the full fiscal year FY26 was INR 2,542 crore, a slight 1% decrease compared to the previous year. Despite this, the strong Q4 performance sets a positive tone for FY27, with management projecting 10-12% volume growth for the upcoming fiscal year. As of March 31, 2026, the company's Net Debt to EBITDA stood at a healthy 0.9x.

Strategic Expansions Fueling Future Growth

The company's recent performance is underpinned by strong operational efficiency and sustained market demand for its products. Epigral is strategically expanding its capacities for key chemicals Epichlorohydrin (ECH) and CPVC. These projects are on track for commissioning in the second quarter of fiscal year 2027.

Formerly known as Meghmani Finechem Ltd, Epigral rebranded in August 2023 to signal a strategic shift towards higher-value specialty chemicals. The company is aggressively increasing its production capabilities, planning to double its CPVC Resin capacity to 150,000 TPA and ECH capacity to 100,000 TPA by the first half of FY27. These expansions, representing an investment of approximately INR 7,800 million, are crucial for driving future revenue and margin growth. The Chlorotoluene value chain plant was commissioned earlier in March 2025.

Market Leadership and Value Creation

Upon commissioning, these expanded capacities will position Epigral as a dominant global player in CPVC resin and a leading producer of ECH in India. The company's focus on import substitution and developing value-added products is expected to further enhance its market share and profitability.

Potential Challenges Ahead

Management has cautioned about potential risks, including the impact of rising geopolitical tensions on global supply chains and raw material prices. Depreciation of the Indian Rupee could affect forex derivatives and increase finance costs. Additionally, volatility in PVC prices may influence CPVC prices and overall demand.

Competitive Positioning

Epigral operates in a competitive sector alongside companies like Deepak Nitrite, which focuses on basic, fine, and specialty chemicals, and Aether Industries, specializing in niche custom-manufactured chemicals for sectors such as agrochemicals and pharmaceuticals. Epigral's integrated model and early-mover advantage in critical specialty chemicals like ECH and CPVC provide distinct competitive strengths.

What to Watch Next

Investors will be closely monitoring several key developments:

• The progress and timely completion of the ECH and CPVC capacity expansions slated for Q2 FY27.
• Any announcements regarding new greenfield projects currently under evaluation.
• Management's commentary on how geopolitical events, currency fluctuations, and PVC price trends are impacting performance.
• The ramp-up of the Chlorotoluene plant commissioned in March 2025 and its contribution to FY27 earnings.